LRRK2 and Parkinson Disease
- 1 May 2010
- journal article
- review article
- Published by American Medical Association (AMA) in Archives of Neurology
- Vol. 67 (5), 542-547
- https://doi.org/10.1001/archneurol.2010.79
Abstract
Review from JAMA Neurology — LRRK2 and Parkinson DiseaseKeywords
This publication has 50 references indexed in Scilit:
- CHIP regulates leucine-rich repeat kinase-2 ubiquitination, degradation, and toxicityProceedings of the National Academy of Sciences of the United States of America, 2009
- Identification of compounds that inhibit the kinase activity of leucine-rich repeat kinase 2Biochemical and Biophysical Research Communications, 2009
- Complete ascertainment of Parkinson disease in the Swedish Twin RegistryNeurobiology of Aging, 2008
- Phosphorylation of 4E-BP by LRRK2 affects the maintenance of dopaminergic neurons in DrosophilaThe EMBO Journal, 2008
- The Parkinson Disease-associated Leucine-rich Repeat Kinase 2 (LRRK2) Is a Dimer That Undergoes Intramolecular AutophosphorylationPublished by Elsevier BV ,2008
- A Drosophila model for LRRK2 -linked parkinsonismProceedings of the National Academy of Sciences of the United States of America, 2008
- The Roc domain of leucine‐rich repeat kinase 2 is sufficient for interaction with microtubulesJournal of Neuroscience Research, 2008
- Identification of potential protein interactors of Lrrk2Parkinsonism & Related Disorders, 2007
- Inhibition of mitogen-activated protein kinase and stimulation of Akt kinase signaling pathways: Two approaches with therapeutic potential in the treatment of neurodegenerative diseasePharmacology & Therapeutics, 2007
- The R1441C mutation of LRRK2 disrupts GTP hydrolysisBiochemical and Biophysical Research Communications, 2007